Navigation Links
Patheon to Host Complimentary Seminar on “Getting Your Drug through Phase I Early Development Effectively” at Milton Park, UK Facility
Date:2/9/2013

(PRWEB) February 08, 2013

Patheon Inc., a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, today announced that it will be hosting a complimentary seminar on “Getting Your Drug Through Phase I Early Development Effectively”. The seminar will be held on Tuesday, February 19th at 11:30 – 6 p.m. Central European Time at Patheon’s Milton Park facility in Oxfordshire, UK.

Patheon recently announced its plans to launch the company’s SoluPath™ program at the Milton Park facility as part of the company’s global strategy to expand early pharmaceutical development services for its customers.

In the upcoming seminar, Patheon have invited three scientific leaders to share their experiences and answer questions on strategies for effectively progressing small molecules through early drug development. Presentations will be provided by Patheon employees, Jon Sutch, Ph.D., and Rick Bastin, as well as from Paul Madeley, Ph.D., with Synth-Isis Ltd. Through case studies and interactive presentations, presenters will discuss early stages of active pharmaceutical ingredient (API) development, formulation strategies and challenges of low solubility and bioavailability. There will also be an opportunity to pose technical questions to the company’s experts through the Ask the Experts round table. Visit Patheon’s website to learn more or register for the upcoming seminar.

About Patheon Inc.

Patheon Inc. (TSX: PTI) is a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Through the company’s recent acquisition of Banner Pharmacaps – a market leader in soft gelatin capsule technology – Patheon now also includes a proprietary products and technology business.

Patheon provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. The company's integrated network consists of 18 locations, including 14 commercial contract manufacturing facilities and 12 development centers across North America and Europe. Patheon enables customer products to be launched with confidence anywhere in the world. For more information visit http://www.patheon.com.

Read the full story at http://www.prweb.com/releases/2013/2/prweb10403198.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Patheon Announces First Phase of Additional Investment in Milton Park, UK Facility to Expand Early Development Capabilities in Europe
2. Local Schools Infested With Bed Bugs, Faculty and Victims Receive Complimentary Bed Bug Spray Samples, MyCleaningProducts.com Explains
3. New No Scrubbing Rust Remover Being Offer As A Complimentary Sample To Save Contractors $1,000, My Cleaning Products Puts The Product To The Test
4. New Ordinance Holds Landlords Responsible To Kill Bed Bugs, My Cleaning Products Offers Complimentary Sample of Bed Bug Bully To Avoid High Exterminator Fee's
5. Medical Diagnostic Laboratories, L.L.C. Announces a Complimentary Reflex Test to Determine Azithromycin Resistance in Chlamydia Trachomatis
6. ComplianceOnline Announces Seminar on Statistical Analysis for Product Development
7. ComplianceOnline Announces Seminar on Clinical Trial Project Supplier Quality Improvement
8. iBioSeminars and iBioMagazine: Free, Online Biology Seminars and Short Talks by Leading Scientists
9. NSG Precision Cells Now Offering a High Grade Flow Through Cell with Unparalled Quality
10. Scientists Describe Breakthrough Technology for Brain Self-Optimization in Newly Published Paper
11. 3D printing breakthrough with human embryonic stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:6/22/2016)... 2016 On Monday, the Department of Homeland ... share solutions for the Biometric Exit Program. The Request ... Protection (CBP), explains that CBP intends to add biometrics ... the United States , in order to deter ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/9/2016)... innovation leader in attendance control systems is proud to announce the introduction of fingerprint ... sure the right employees are actually signing in, and to even control the opening ... ... ... Photo ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
Breaking Biology News(10 mins):